NCT07139353View on ClinicalTrials.gov

Linperlisib Combined With Chidamide in the Treatment of Relapsed or Refractory Peripheral T-cell Lymphoma

PHASE1/PHASE2Not yet recruitingINTERVENTIONAL
Enrollment

54

Participants

Timeline

Start Date

September 15, 2025

Primary Completion Date

September 1, 2027

Study Completion Date

September 1, 2029

Conditions
Peripheral T Cells Lymphoma (PTCL)
Interventions
DRUG

Linperlisib

Linperlisib: 80 mg or 60 mg, po, qd (phase Ib); RP2D (phase II)

DRUG

Chidamide

Chidamide: 20mg, po, biw

All Listed Sponsors
lead

Sun Yat-sen University

OTHER